
Immatics scores $75M upfront in TCR deal with Celgene as interest in tech burgeons
Months after elevating its chief scientist, Harpreet Singh, to the post of CEO, privately-held immuno-oncology company Immatics has enlisted another partner — Celgene — in a deal capitalizing on the industry appetite for TCR therapies and their potential to target solid tumors — a limitation of existing cellular therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.